Physician profile
Lawrence Negret
NPI 1033107156
$10,513.02
in general payments reported to CMS, 2019-2025
53 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,901 · 2020: $1,120 · 2021: $1,308 · 2022: $636 · 2023: $1,442 · 2024: $933 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,432 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,431.80 |
| Education | $116.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $1,586.35 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $897.28 | 2019-2025 | Keytruda, Keytruda Qlex |
| Janssen Biotech, INC. | $851.14 | 2019-2025 | Rybrevant, Erleada, Tecvayli |
| Novartis Pharmaceuticals Corporation | $779.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $650.28 | 2019-2025 | Enhertu, Imfinzi |
| Lilly USA, LLC | $572.29 | 2019-2025 | Verzenio |
| Pfizer INC. | $561.85 | 2019-2025 | |
| Emd Serono, INC. | $542.83 | 2021-2024 | |
| Seagen INC. | $347.05 | 2019-2024 | Tukysa |
| Amgen INC. | $271.01 | 2019-2025 | Kyprolis, Blincyto, Imdelltra (Amg757) |
| E.R. Squibb & Sons, L.L.C. | $261.41 | 2019-2025 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $256.73 | 2019-2025 | Libtayo, Lynozyfic |
| Genzyme Corporation | $235.12 | 2019-2022 | |
| Celgene Corporation | $220.53 | 2019-2025 | Reblozyl |
| Novocure Gmbh | $200.00 | 2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Negret listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.